Five-year follow-up of waist circumference, insulin and ALT levels in familial combined hyperlipidaemia

Brouwers, Martijn C.G.J.; Greevenbroek, Marleen M.J. van; Vermeulen, Vicky M. M.-J.; Lin, Josephine M.J.P. van; Kallen, Carla J.H. van der; Bruin, T.W.A. de

doi:10.1042/cs20070101

Cited by 8 publications

(11 citation statements)

References 37 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, in the present study, we investigated the presence of such a parabola in two previously reported well-defined FCHL cohorts that have been followed over time, i.e. the Maastricht and Nijmegen FCHL cohorts [11,13]. In addition, we studied the longitudinal relationship between plasma triacylglycerols and apoB, hallmarks of FCHL, and the prevalence of CVD (cardiovascular disease), the clinically relevant end point of FCHL.…”

Section: Introductionmentioning

confidence: 97%

“…More recently, another metabolic factor, i.e. hepatic fat as reflected by plasma alanine aminotransferase levels, was added to this list in a second Dutch FCHL cohort [13]. As the metabolic pathways contributing to the switch in triacylglycerol phenotype are being elucidated, no factors have yet been linked to the switch in cholesterol phenotype.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Parabolic relationship between plasma triacylglycerols and LDL-cholesterol in familial combined hyperlipidaemia: the multiple-type hyperlipidaemia explained?

et al. 2008

Self Cite

View full text Add to dashboard Cite

FCHL (familial combined hyperlipidaemia) is a highly prevalent genetic lipid disorder that accounts for a substantial number of premature cardiovascular events. To date, FCHL has been complicated by the different lipid phenotypes that are present within one family and one individual patient over time. In the present study, we hypothesized that a parabolic relationship between plasma triacylglycerols (triglycerides) and LDL (low-density lipoprotein)-cholesterol can explain this so-called 'multiple-type hyperlipidaemia' in FCHL. Our hypothesis was tested in two well-documented FCHL cohorts [Maastricht (n=145) and Nijmegen (n=299)] that were followed over a 5-year interval. Three groups were constructed depending on plasma triacylglycerols: group A (individuals with both measurements below 1.5 mmol/l), group B (one measurement below and one measurement above 1.5 mmol/l) and group C (both measurement above 1.5 mmol/l). In both male, but not female, cohorts, a significant positive relationship between plasma triacylglycerols and LDL-cholesterol was observed in group A (P=0.02 for Maastricht cohort and P=0.001 for the Nijmegen cohort), a significant negative relationship in group C (P=0.01 for Maastricht cohort and P=0.02 for the Nijmegen cohort), and a relationship intermediate to group A and C in group B. In contrast, both apoB (apolipoprotein B) levels and the prevalence of cardiovascular disease were related with plasma triacylglycerols in a more linear fashion. In conclusion, a parabolic relationship between plasma triacylglycerols and LDL-cholesterol explains the 'multiple-type hyperlipidaemia' in FCHL. In addition, the linear relationship between triacylglycerols and both apoB levels and the prevalence of cardiovascular disease substantiate the use of apoB instead of LDL-cholesterol in the diagnosis of FCHL and the prediction of cardiovascular disease.

show abstract

Section: Introductionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Parabolic relationship between plasma triacylglycerols and LDL-cholesterol in familial combined hyperlipidaemia: the multiple-type hyperlipidaemia explained?

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

“…As the study by Brouwers et al [3], which appears in this issue of Clinical Science, confirms, time modifies the dyslipidaemic phenotype in FCHL. Our genes do not change over time.…”

mentioning

confidence: 61%

“…What is interesting is that this relationship was much more obvious in the FCHL family members than in their spouses [3]. Thus this study provides further evidence that FCHL is the outcome of a nature-nurture interaction.…”

mentioning

confidence: 71%

“…Brouwers et al [3] demonstrate that as abdominal obesity developed in family members with FCHL, so did hypertriglyceridaemia, hyperinsulinaemia and increased hepatic triacylglycerol (triglyceride) content as reflected in plasma ALT (alanine aminotransferase) levels. What is interesting is that this relationship was much more obvious in the FCHL family members than in their spouses [3].…”

mentioning

confidence: 98%

See 1 more Smart Citation

Familial combined hyperlipidaemia: how can genetic disorders be common, complex and comprehensible?

2007

View full text Add to dashboard Cite

FCHL (familial combined hyperlipidaemia) is characterized by multiple phenotypes that are shaped by genes, the environment and time. A longitudinal study by Brouwers and co-workers, which appears in this issue of Clinical Science, points to the central role of the liver in defining the FCHL phenotypes and demonstrates how they vary over time in relation to energy excess. On the basis of their work and that of others, we propose that FCHL is a multiple gene/multiple pathway/multiple phenotype disease. The key feature of this model of common complex disease is that it posits testable faults in definable metabolic pathways, which supply the genetic underpinning of the disorder.

show abstract

Hiperlipidemia familiar combinada: documento de consenso

Mata¹,

Alonso

Ruiz‐García³

et al. 2014

Atención Primaria

View full text Add to dashboard Cite

Familial combined hyperlipidemia (FCH) is a frequent disorder associated with premature coronary artery disease. It is transmitted in an autosomal dominant manner, although there is not a unique gene involved. The diagnosis is performed using clinical criteria, and variability in lipid phenotype and family history of hyperlipidemia are necessaries. Frequently, the disorder is associated with type2 diabetes mellitus, arterial hypertension and central obesity. Patients with FCH are considered as high cardiovascular risk and the lipid target is an LDL-cholesterol <100mg/dL, and <70mg/dL if cardiovascular disease or type 2 diabetes are present. Patients with FCH require lipid lowering treatment using potent statins and sometimes, combined lipid-lowering treatment. Identification and management of other cardiovascular risk factors as type 2 diabetes and hypertension are fundamental to reduce cardiovascular disease burden. This document gives recommendations for the diagnosis and global treatment of patients with FCH directed to specialists and general practitioners.

show abstract

Five-year follow-up of waist circumference, insulin and ALT levels in familial combined hyperlipidaemia

Cited by 8 publications

References 37 publications

Parabolic relationship between plasma triacylglycerols and LDL-cholesterol in familial combined hyperlipidaemia: the multiple-type hyperlipidaemia explained?

Parabolic relationship between plasma triacylglycerols and LDL-cholesterol in familial combined hyperlipidaemia: the multiple-type hyperlipidaemia explained?

Familial combined hyperlipidaemia: how can genetic disorders be common, complex and comprehensible?

Hiperlipidemia familiar combinada: documento de consenso

Contact Info

Product

Resources

About